Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P,
Marsden CD. 1989. Basal lipid peroxidation in substantia nigra is in- creased in Parkinson's disease. J Neurochem 52:381–389.
Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cue ́nod
M, Holsboer F. 1995. Gamma-glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients
with schizophrenic disorders. J Neurochem 65:2652–2662.
Do KQ, Trabesinger AH, Kirsten-Kru ̈ ger M, Lauer CJ, Dydak U, Hell D,
Holsboer F, Boesiger P, Cue ́nod M. 2000. Schizophrenia: glutathione
deficit in cerebro spinal fluid and prefrontal cortex in vivo. Eur J Neurosci
12:3721–3728.
Dobbing J, Sands J. 1979. Comparative aspects of the brain growth spurt.
Early Hum Dev 3:79 – 83.
Dringen R. 2000. Metabolism and functions of glutathione in brain. Progr
Neurobiol 62:649 – 671.
Ellender G, Gazelakis T. 1996. Growth and bone remodelling in a scorbutic
rat model. Aust Dent J 41:97–106.
Farooqui AA, Horrocks LA. 1998. Lipid peroxides in the free radical
pathophysiology of brain diseases. Cell Mol Neurobiol 18:599 – 608.
Finlay JM. 2001. Mesoprefrontal dopamine neurons and schizophrenia: role
of developmental abnormalities. Schizophr Bull 27:431– 442.
Flohe ́ L, Otting F. 1984. Superoxide dismutase assays. Methods Enzymol
105:93–104.
Gabbay M, Tauber M, Porat S, Simantov R. 1996. Selective role of
glutathione in protecting human neuronal cells from dopamine-induced
apoptosis. Neuropharmacology 35:571–578.
Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG.
1998. Re-evaluation of the role of the dopamine transporter in dopamine
system homeostasis. Brain Res Brain Res Rev 26:148 –153.
Glowinski J, Iversen LL. 1966. Regional studies of catecholamines in the rat
brain—I the disposition of [3H]dopamine and [3H]DOPA in various
regions of the brain. J Neurochem 13:655– 669.
Gluck MR, Jayatilleke E, Shaw S, Rowan AJ, Haroutunian V. 2000. CNS
oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res 39:63–71.
Go ̈ tz ME, Janetzky B, Pohli S, Gottschalk A, Gsell W, Tatschner T,
Ransmayr G, Leblhuber F, Gerlach M, Reichmann H, Riederer P,
Bo ̈ ning J. 2001. Chronic alcohol consumption and cerebral indices of
oxidative stress: is there a link? Alcohol Clin Exp Res 25:717–725.
Harrison PJ. 1999. The neuropathology of schizophrenia. A critical review
of the data and their interpretation. Brain 122(Pt 4):593– 624.
Heales SJR, Bolan~ os JP, Stewart VC, Brookes PS, Land JM, Clark JB. 1999.
Nitric oxide, mitochondria and neurological disease. Biochim Biophys
Acta Bioenerg 1410:215–228.
Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD,
Markesbery WR. 1994. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci Lett 182:87–
90.
Jones DC, Gunasekar PG, Borowitz JL, Isom GE. 2000. Dopamineinduced apoptosis is mediated by oxidative stress and is enhanced by
cyanide in differentiated PC12 cells. J Neurochem 74:2296 –2304.
Junn E, Mouradian MM. 2001. Apoptotic signaling in dopamine-induced
cell death: the role of oxidative stress, p38 mitogen-activated protein
kinase, cytochrome c and caspases. J Neurochem 78:374 –383.
Kim HC, Jhoo WK, Bing G, Shin EJ, Wie MB, Kim WK, Ko KH. 2000.
Phenidone prevents kainate-induced neurotoxicity via antioxidant mechanisms. Brain Res 874:15–23.
Lefe`vre G, Beljean-Leymarie M, Beyerle F, Bonnefont-Rousselot D, Cristol JP, The ́rond P, Torreilles J. 1998. Evaluation of lipid peroxidation by
measuring thiobarbituric acid reactive substances. Ann Biol Clin 56:305–
319.
Lin AMY. 2001. Coexistence of zinc and iron augmented oxidative injuries
in the nigrostriatal dopaminergic system of SD rats. Free Radic Biol Med
30:225–231.
